Novo Nordisk tests grand acquisition in phase III trial
Pharmaceutical giant Novo Nordisk is testing a hormone test for diagnosing children with growth hormone deficiency in a phase III trial. Novo Nordisk bought the test back in 2018 for DKK 1.2bn as part of the firm's market race where it's competing with Ascendis Pharma on producing growth hormones.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has great expectations for the growth hormone market, where the pharmaceutical company is currently in competition with Danish biotech company Ascendis Pharma.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.